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Introduction
============

The magnitude of cerebrovascular disease (CVD) related to coronary catheterization is high and sometimes severe. It is considered one of the most severe complications after coronary angiography (CAG). We have observed the occurrence of CVD complications after percutaneous coronary intervention (PCI) as well as after the only examination technique such as CAG. Although the frequency of symptomatic CVD complications was explained to patients filling the catheter examination consent form at our facility, the frequency of asymptomatic CVD complications was not explained completely in the real clinical practice because it has not been substantially investigated.

Previous studies have reported the rate of symptomatic CVD complications after CAG and PCI to be 0.1%--1%^[@bib1]--[@bib3])^ and 0.1%--0.6%^[@bib4]--[@bib9])^, respectively. However, the rate of asymptomatic CVD is 10.2%--22%, which is significantly higher than that of symptomatic CVD^[@bib10]--[@bib13])^. In addition, there are multiple risk factors of CVD after PCI and CAG including advanced age, hypertension, diabetes mellitus (DM), prior stroke, and the use of intra-aortic balloon pumping (IABP)^[@bib9],\ [@bib13]--[@bib16])^. It has been shown that CVD after CAG or PCI is associated with a poor prognosis^[@bib9],\ [@bib14]--[@bib16])^. Recently, cardiac catheterization has shifted from the femoral artery to the radial artery approach, and slender catheters such as 4 Fr or 5 Fr catheters are commonly used. In addition, because of the aging Japanese population, CAG and PCI are being performed even in those aged ≧ 75 years. Because few studies have reported on the relationship between CVD complications after CAG or PCI and the procedural data such as puncture site, dosage of contrast medium, procedure time, catheter size, CVD complication risks remains unknown in Japan. Therefore, we investigated the incidence and risk factors of CVD complication within 48 h after CAG using diffusion-weighted magnetic resonance imaging (DW-MRI) at our institute.

Methods
=======

Subjects and Study Protocol
---------------------------

We conducted a prospective study including patients who underwent CAG and were admitted to Kagoshima University Hospital between September 2013 and April 2015. In the patients who underwent several CAG, the first CAG was used in this study. Patients who corresponded to MRI exclusion criteria and were considered inappropriate by the physician were excluded from the study. The patients underwent MRI of their heads within 48 h after CAG, with or without symptoms, and MRI interpretation was performed immediately by a radiologist in a blinded manner.

All patients gave their written informed consent prior to participating in the study and were the subjects of this analysis. This study complied with the standards of the Declaration of Helsinki and current ethical guidelines, and it was approved by the institutional ethics board at Kagoshima University Hospital. Maximum effort was taken by all involved in this study to ensure anonymity and protection of subject information. We referred to the case identification cord instead of the medical record number of each subject.

Coronary Angiography
--------------------

CAG was performed by well-trained cardiologists according to the standardized Judkins method. All patients underwent CAG using 4 to 6 Fr catheters via femoral or radial access, as selected based on the operator\'s judgment. In addition, we did not perform the left ventricle (LV) graphy routinely in the patients with aortic stenosis because there is a possibility of high rate of CVD complications. Before starting the procedure, patients were administered 3000 U of unfractionated heparin intravenously. A non-ionic iso-osmolar contrast medium was used during CAG. The total fluoroscopy time was measured in all cases.

Measurements
------------

Blood specimens for the measurement of BNP and lipoprotein (a) levels were collected at the time of admission. A blood sample for the measurement of Cystatin C was collected before CAG.

Hypertension was defined as having systolic blood pressure ≧ 140 mmHg, diastolic blood pressure ≧ 90 mmHg, or by the use of antihypertensive drugs. DM was defined as having an HbA1c level of ≥ 6.5%, or occasionally, a blood glucose level of ≧ 200 mg/dL, fasting blood glucose level of ≧ 126 mg/dl, or a history of treatment for diabetes. Dyslipidemia was defined as having a low-density lipoprotein cholesterol level of ≧ 140 mg/dL, triglyceride level of ≧ 150 mg/dL, high-density lipoprotein cholesterol level of ≦ 40 mg/dL, or the use of lipid-lowering drugs such as statin and fibrates. CAD was defined as a diameter stenosis of the presence of ≧ 1 vessel with ≧ 70% luminal diameter narrowing, as detected by CAG during the present study or previous CAG by the American College of Cardiology/American Heart Association for lesion classification in three coronary arteries^[@bib17])^. Prior heart failure was defined as having a principal discharge diagnosis of heart failure. Aortic stenosis was defined as mild or over, and aortic regurgitation was defined as trace or over, according to the guidelines^[@bib18])^.

MRI
---

DW-MRI of the brain \[1.5- or 3-Tesla (T) Achieva Nova Dual, Philips Medical Systems, Netherlands\] was performed within 48 h after CAG. The imaging protocol included DW single-shot spin echo-planar imaging \[repetition time (TR): 4500 ms (1.5-T), 4000 ms (3-T); echo time (TE): 74 ms (1.5-T), 87 ms (3-T); slice thickness: 5 mm (1.5-T and 3-T); interslice gap: 1 mm (1.5-T and 3-T); 24 axial slices (1.5-T and 3-T); matrix: 102 × 128 (1.5-T and 3-T); field view: 220 mm (1.5-T and 3-T); diffusion gradient: b values of 0 and 1000 s/mm^2^ (1.5-T and 3-T, respectively)\], fluid-attenuated inversion recovery \[TR/TE/inversion time (TI): 9000/119/2500 ms (1.5-T), 9000/123/2500 ms (3-T)\], and T2- weighted turbo spin echo \[TR/TE: 4000/89 (1.5-T), 4000/87 ms (3-T)\] sequences. All MRI findings were analyzed by 2 radiologists in a blinded manner. We diagnosed acute embolic infarction using the combination of DW and apparent diffusion coefficient (ADC) map findings.

Statistical Analysis
--------------------

Descriptive statistics are presented as frequency (percentage) for categorical variables and mean +/− standard deviation or median (interquartile range) for continuous variables. The data were compared using a chi-square or Fisher\'s exact test for a categorical variable, a two-sample *t*-test for normal distribution, or the Wilcoxon rank sum test for non-normal distribution of continuous variables. 95% confidence interval (CI) of binominal proportions was calculated using the adjusted Wald method^[@bib19])^. A multiple logistic regression model was used to assess CVD risk factor complications that were expressed as odds ratios with a 95% CI, and adjusted by which a dummy variable was the advanced age assigned 75 years old and more as 1. All analyses were conducted using JMP 12.0 (SAS Institute Inc, Cary, NC). All statistical analyses were two-tailed, and *P* value \< 0.05 was considered statistically significant.

Results
=======

Baseline Characteristics
------------------------

The baseline characteristics of the patients are shown in **[Table 1](#T1){ref-type="table"}**. The mean age was 70.0 ± 10.2 years, and 43 (70%) patients were male. Of the 61 patients, 25 (41%) presented with DM, 41 (67%) with dyslipidemia, 44 (72%) with hypertension, and 5 (8.2%) with atrial fibrillation. 28 (46%) patients underwent PCI and 5 (8.2%) underwent CABG. In addition, 14 (23%) patients had prior myocardial infarction. In terms of procedural characteristics, a catheter size of \< 5 Fr was frequently used (67%), mean procedural time was 66.5 ± 19.9 min, and 10 (16%) patients underwent CAG via the femoral artery. Ergonovine provocation test was performed in 9 patients (15%), angiography of the internal mammary arteries (IMA) was performed in 1 patient (1.6%), and angiography of the saphenous vein was not done at all. Additionally, LV graphy was performed in 4 (6.6%) patients (**[Table 2](#T2){ref-type="table"}**). Regarding baseline medications, no significant difference was observed in the use of antiplatelet drugs, statins, beta-blockers, warfarin, or direct oral anticoagulants (DOAC).

###### Baseline Characteristics of Patients with (CVD) and without (non-CVD) Stroke after CAG

  Variables                          All patients         CVD                  non-CVD            *P* value
  ---------------------------------- -------------------- -------------------- ------------------ -----------
  \(A\) Clinical characteristics                                                                  
      Age (years)                    70.0 ± 10.2          65.5 ± 4.2           70.5 ± 1.4         0.3
          Age \> = 75 years          23 (38%)             1 (17%)              22 (40%)           0.4
      Male                           43 (70%)             3 (50%)              40 (73%)           0.3
      BMI                            23.9 ± 4.0           23.8 ± 1.6           23.9 ± 0.5         0.97
          BMI \< 25.0                36 (59%)             3 (50%)              33 (60%)           0.7
      Hypertension                   44 (72%)             3 (50%)              41 (75%)           0.3
      Diabetes mellitus              25 (41%)             1 (17%)              24 (44%)           0.4
      Dyslipidemia                   41 (67%)             5 (83%)              36 (65%)           0.7
      Current smoking                11 (18%)             1 (17%)              10 (18%)           1.0
      Prior Heart failure            8 (13%)              1 (17%)              7 (13%)            1.0
      Coronary artery disease        43 (70%)             4 (67%)              39 (71%)           1.0
      Multi-vessel disease           19 (31%)             3 (50%)              16 (29%)           0.4
      Aortic stenosis                7 (11%)              1 (17%)              6 (11%)            0.5
      Aortic regurgitation           22 (36%)             3 (50%)              19 (35%)           0.7
      Mitral regurgitation grade ¾   8 (13%)              1 (17%)              7 (13%)            1.0
      Ejection fraction              61.4 (48.5--69)      58.5 (50.5--68.3)    62 (47.9--74.5)    0.7
      Ejection fraction \< 40%       6 (9.8%)             1 (17%)              5 (9.1%)           0.5
      Prior PCI                      28 (46%)             2 (33%)              26 (47%)           0.7
      Prior CABG                     5 (8.2%)             2 (33%)              3 (5.5%)           0.07
      Prior myocardial infarction    14 (23%)             1 (17%)              13 (24%)           1.0
      Prior Stroke                   6 (9.8%)             0 (0%)               6 (11%)            1.0
      Aortic aneurysm/dissection     9 (1.8%)             1 (17%)              8 (15%)            1.0
      Peripheral vascular disease    9 (1.8%)             1 (17%)              8 (15%)            1.0
      eGFR \< 60, not on dialysis    18 (30%)             1 (17%)              17 (31%)           0.7
      Dialysis                       2 (3.2%)             1 (17%)              1 (1.8%)           0.2
      Atrial fibrillation            5 (8.2%)             0 (0%)               5 (9.1%)           1.0
      Anemia (Hb \< 11.0g/dL)        10 (16%)             1 (17%)              9 (16%)            1.0
      Platelets \< 100 × 10^9^/L     1 (1.6%)             0 (0.0%)             1 (1.8%)           1.0
      COPD                           5 (8.2%)             0 (0.0%)             5 (9.1%)           1.0
      Liver hepatitis                2 (3.2%)             0 (0.0%)             2 (3.6%)           1.0
      Malignancy                     7 (11%)              0 (0%)               7 (13%)            1.0
      mean PWV                       1785 ± 463           1994 ± 973           1762 ± 378         0.6
      mean CAVI                      8.8 ± 1.6            8.0 ± 1.2            8.9 ± 1.6          0.2
      BNP                            52.6 (26.4--111.6)   56.5 (41.6--712.6)   52.6 (26--109.4)   0.5
      Lp (a)                         15.4 (6.5--32.5)     14.4 (5.6--29.6)     15.4 (6.5--33)     0.8
      Cystatin C                     1.08 (0.93--1.3)     1.09 (0.82--2.7)     1.08 (0.93--1.3)   0.9
  \(B\) Baseline Medications                                                                      
      Antiplatelet therapy                                                                        
          Thienopyridine             36 (59%)             3 (8.3%)             33 (92%)           0.7
              Ticlopidine            7 (11%)              0 (0%)               7 (13%)            1.0
              Clopidogrel            29 (48%)             3 (50%)              26 (47%)           1.0
          Aspirin                    46 (75%)             5 (83%)              41 (75%)           1.0
          Cilostazol                 1 (1.6%)             0 (0%)               1 (1.8%)           1.0
      Other medications                                                                           
          Statins                    40 (66%)             4 (67%)              36 (65%)           1.0
          Beta-blockers              22 (36%)             1 (17%)              21 (38%)           0.4
          ACE-I/ARB                  37 (61%)             3 (50%)              34 (62%)           0.7
          Nitrates                   7 (11%)              1 (17%)              6 (11%)            0.5
          Calcium channel blockers   31 (51%)             1 (17%)              30 (55%)           0.1
          Nicorandil                 30 (49%)             2 (33%)              28 (51%)           0.7
          Warfarin                   7 (11%)              1 (17%)              6 (11%)            0.4
          DOAC                       1 (1.6%)             0 (0%)               1 (1.8%)           1.0

Continuous variables are shown as mean ± SD or median (interquartile range).

ACE-I = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, BMI = body mass index, BNP = brain natriuretic peptide, CABG = coronary artery bypass grafting, CAVI = cardio ankle vascular index, COPD = chronic obstructive pulmonary disease, CVD = cerebrovascular disease, DOAC = direct oral anticoagulants, eGFR = estimated glomerular filtration rate, Hb = hemoglobin, Lp (a) = lipoprotein (a), LV = left ventricle, PCI = percutaneous coronary intervention, and PWV = pulse wave velocity.

###### Procedural Characteristics of Patients with (CVD) and without (non-CVD) Stroke after CAG

  Variables                        All patients   CVD           non-CVD       *P* value
  -------------------------------- -------------- ------------- ------------- -----------
  Dose of Heparin \< 3000 U        2 (3.3%)       0 (0%)        2 (3.6%)      1.0
  Procedural time (min)            66.5 ± 19.9    61.3 ± 12.9   67.1 ± 20.5   0.5
  Dosage of contrast medium        68.8 ± 34.8    55.8 ± 26.2   70.3 ± 35.4   0.3
  Femoral artery catheterization   10 (16%)       1 (17%)       9 (16%)       1.0
  EM provocation                   9 (15%)        1 (17%)       8 (15%)       1.0
  SVG angiography                  0 (0%)         0 (0%)        0 (0%)        --
  IMA angiography                  1 (1.6%)       0 (0%)        1 (1.8%)      1.0
  LV graphy                        4 (6.6%)       0 (0%)        4 (7.3%)      1.0

CAG = coronary angiography, EM = ergonovine malate, IMA = internal mammary artery, LV = left ventricle, and SVG = saphenous vein graft.

The Incidence and Location of CVD Complications
-----------------------------------------------

The incidence of asymptomatic cerebral infarction (CI) complication after CAG was 9.8% (6 cases), with a mid-point percentage 11.1% (95% Confidence Interval: 4.3%--20.2%) calculated using the adjusted Wald method. Symptomatic cerebral infarction or symptomatic and asymptomatic cerebral hemorrhage was not observed. There were 2 cases (case 1 and 6) with an infarct lesion size \> 3 mm. **[Table 3](#T3){ref-type="table"}** shows the location of stroke and procedural data of CAG in each patient with asymptomatic stroke after CAG. **[Fig. 1](#F1){ref-type="fig"}** shows MRI images of each patient with stroke after CAG. Only case 3 developed a cerebral infarct at two sites, whereas other cases presented with a cerebral infarct at only one site. Only one case underwent CAG via the right femoral approach, whereas the approach site of other cases was via the right radial artery. No cases underwent any IMA angiography and IABP, which were reported as risk factors of CVD after CAG or PCI.

###### Location of Stroke and Procedural Data from each patient with Stroke after CAG

  Case No.   Location of stroke                       Diagnosis after CAG          Age   Sex   Ergonovine test   Catheter size (Fr)   Heparin (U)   Procedural time (min)   Contrast medium (mL)   Access site
  ---------- ---------------------------------------- ---------------------------- ----- ----- ----------------- -------------------- ------------- ----------------------- ---------------------- ---------------
  1          left corona radiata                      Vasospastic angina           68    F     present           5                    3000          75                      60                     right radial
  2          splenium of corpus callosum              Silent myocardial ischemia   61    M     absent            6                    3000          73                      60                     right radial
  3          right thalamus and right parietal lobe   Unstable angina              65    M     present           4                    3000          50                      100                    right radial
  4          right cerebellar hemisphere              Aortic regurgitation         52    F     absent            5                    3000          55                      50                     right femoral
  5          right frontal lobe                       Abdominal aortic aneurysm    65    M     absent            4                    3000          70                      20                     right radial
  6          left cerebellar hemisphere               Silent myocardial ischemia   82    F     absent            4                    3000          45                      45                     right radial

CAG = coronary angiography, IMA = internal mammary artery, and SVG = saphenous vein graft.

![DW-MRI images in each patient with stroke after CAG.\
A yellow arrow shows acute embolic lesion which was characterized by a bright hyperintense lesion on DW and ADC maps.](jat-25-224-g001){#F1}

Baseline Characteristics: CVD Group vs. Non-CVD Group
-----------------------------------------------------

We compared the baseline characteristics of patients with (CVD group, *n* = 6) and without (non-CVD group, *n* = 55) CVD complications.

Age, sex, DM, dyslipidemia, hypertension, multivessel disease, aortic stenosis, ejection fraction, prior myocardial infarction, and atrial fibrillation were similar between CVD and non-CVD groups. In addition, regarding procedural data, there was no significant difference in catheter size, heparin dosage, procedural time, access site, and LV graphy between both groups.

In terms of medication, no significant difference was observed in the use of antiplatelet drugs, warfarin, and DOAC. Prior CABG was more frequently found in the CVD group (2/6 cases, 33%) than that in the non-CVD group (3/55 cases, 5.5%); however, no significant difference was observed (*P* = 0.07).

Independent Risk Factors for CVD Complications
----------------------------------------------

We performed a multiple logistic regression analysis after adjusting for age, sex, and prior CABG to identify the independent risk factors for CVD complications after CAG, because age and sex are the important meaningful factor in the clinical practice and only prior CABG was tended to be more frequently in the CVD group than in the non-CVD group. Our results demonstrated that prior CABG was a significant independent risk factor for the incidence of stroke after CAG (OR: 11.7, 95%CI: 1.14--129.8, *P* = 0.04) (**[Table 4](#T4){ref-type="table"}**).

###### A multiple logistic regression model to identify the independent risk factors for CVD after CAG

  Variables        Present       Absent        Univariate          Multivariate                        
  ---------------- ------------- ------------- ------------------- -------------- -------------------- ------
  Prior CABG       2/5 (40%)     4/56 (7.1%)   8.67 (0.94--70.5)   0.06           11.7 (1.14--129.8)   0.04
                                                                                                       
  Age ≥ 75 years   1/23 (4.4%)   5/38 (13%)    0.30 (0.02--2.03)   0.2            0.24 (0.01--2.14)    0.2
  Male             3/43 (7.0%)   3/18 (17%)    0.38 (0.06--2.22)   0.3            0.22 (0.02--1.55)    0.1

CABG = coronary artery bypass grafting, CAG = coronary angiography, CI = confidence interval, CVD = cerebrovascular disease, OR = odds ratio

Discussion
==========

The incidence of asymptomatic CI complications after CAG was 9.8% (6 cases); however, symptomatic or asymptomatic cerebral hemorrhage was not observed. In addition, prior CABG was a significant independent risk factor for the incidence of stroke after CAG, after adjusting for age and sex.

Previous studies have reported a 10.2%--22% incidence of asymptomatic CI after CAG^[@bib11],\ [@bib13],\ [@bib20])^. Omran *et al.* reported a significantly high incidence rate (22%) of CI after retrograde catheterization of the aortic valve^[@bib11])^. Recently, Morita *et al.* reported that of the 84 patients who underwent MRI after catheterization, acute CI was found in 27 (32.1%) patients and the rate of CI after catheterization was significantly higher than other studies. However, because this study was a retrospective analysis and MRI was not performed for the series of catheterization procedures, the rate of CI may have been considerably overestimated^[@bib21])^. In Korea, the incidence of asymptomatic CI after CAG performed before CABG and detected by MRI was 10.2% (20/197 patients), with IMA angiography as the independent risk factor^[@bib13])^. We speculated that the incidence of stroke after PCI increased slightly compared with that after CAG because of the increase in time and complexity of the procedure. In an analysis of 9662 patients who underwent PCI, the incidence of symptomatic stroke after the procedure was 0.38% and the risk factors included the use of IABP, advanced age (\> 80 years), and vein graft intervention^[@bib15])^. A prospective study in Germany reported that 7 (15%) of 48 patients exhibited 9 focal CI after cardiac catheterization, with duration of the procedure as an independent predictor of CI occurrence^[@bib10])^. IMA angiography is commonly performed both before and after CABG to confirm the presence and location. Similarly, vein graft angiography is usually performed after CABG. Therefore, patients who underwent IMA angiography and vein graft angiography either before or after CABG may have severe arteriosclerosis with multiple coronary stenosis. The performance of IMA angiography and vein graft after CABG decreased because the presence and location of IMA and vein graft were confirmed by CT-angiography instead of catheterization. Because the performance of IMA and saphenous vein graft (SVG) angiography was very low in this study, a significant difference between CVD and non-CVD groups was not observed. Therefore, we speculate that it is reasonable to consider prior CABG as a significant independent risk factor for the incidence of CI after CAG.

The complications of postprocedural CVD in CAG and PCI have been reported to be caused by thrombus formation in the catheter itself and lumen, attachment of the thrombus to the exchange wire, air embolisms, and debris from arteriosclerosis dislodged by guide catheter^[@bib22]--[@bib24])^. In accordance with previous studies, we found that asymptomatic CI was observed in 9.8% of the patients in our study. Even with the recent use of a small diameter catheter such as the 4 Fr catheter, the incidence of CI did not differ compared with that when a larger size catheter was used. In addition, we demonstrated that all procedural data including heparin dosage, procedural time, and dosage of contrast medium were not risk factors of CVD. The procedures were performed only by skilled operators, so that no unsuccessful cases were reported. This study included cases with only CAG, and without PCI, which minimized catheter-related complications. In a 2012 report from Europe, 165 patients with advanced aortic valve stenosis were assigned to either the femoral artery approach or the radial artery approach, and 77 patients from the femoral artery group and 83 patients from the radial artery group were analyzed. Asymptomatic CI detected by DW-MRI was not significantly different between the femoral artery and radial artery groups (11.7% vs 17.5%, respectively, *P* = 0.31). The independent risk factors were high height and low aortic pressure gradient^[@bib25])^. Considering that the catheter in the radial artery group did not pass through the aortic arch, it was likely that the incidence of CI in this group was lesser than that in the femoral artery group; however, no significant difference was reported between two groups. We speculated that the postprocedural CVD complications in the recently developed catheterization procedure was not affected significantly by the procedure itself, which did not contribute as a risk factor of CVD.

In previous studies, the in-hospital mortality rate after symptomatic CVD complications during catheter examination and treatment has been reported to be 22%--37%, which is a very poor prognosis^[@bib9],\ [@bib14],\ [@bib15],\ [@bib26],\ [@bib27])^. Although spontaneous asymptomatic CI increases with age, it has been reported to be 8%--28% across all generations^[@bib28])^. In patients with cardiovascular disease, the incidence of asymptomatic CI is known to be extremely high^[@bib29],\ [@bib30])^. Recent report demonstrated that the incidence rate of non-fatal stroke for 3-years after PCI in the drug-eluting stent era in patients with renal insufficiency was 3.8%^[@bib31])^. Furthermore, silent brain infarction is associated with a 2-fold increased risk of future stroke^[@bib32])^.

Study Limitations
=================

There are several limitations in this study. First, the present study is an observational study; therefore, unknown risk factors may exist. However, we extracted detailed data as much as possible. Secondly, 61 cases from a single facility is a small sample size and statistically insufficient to investigate the risk factors of CVD. Further studies with large sample sizes are required. Finally, because the procedures, particularly the access site of the catheter, were not allocated in this study, we could not clarify the difference among the procedures.

Conclusions
===========

The incidence of the asymptomatic CI detected by MRI after CAG was 9.8%, but no onset of symptomatic CI was observed. Only prior CABG was found to be an independent risk factor for the development of asymptomatic CI. We suggest that the incidence of CI after CAG was not related to the catheterization procedure per se but caused by severe atherosclerosis and multiple coronary stenosis in patients who underwent CABG.
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